Illumina, Inc.

ILMN

US4523271090

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 11:21:12 2026-02-11 am EST			5-day change	1st Jan Change
118.94 ^USD	-0.31%		-12.06%	-10.03%

Feb. 06	UBS Adjusts Illumina Price Target to $135 From $120, Maintains Neutral Rating	MT
Feb. 05	Illumina, Inc., Q4 2025 Earnings Call, Feb 05, 2026

Illumina introduces Billion Cell Atlas, genome-wide genetic perturbation dataset

Published on 01/13/2026 at 11:02 am EST

Reuters

Latest news about Illumina, Inc.

Feb. 06	UBS Adjusts Illumina Price Target to $135 From $120, Maintains Neutral Rating	MT
Feb. 05	Illumina, Inc., Q4 2025 Earnings Call, Feb 05, 2026
Feb. 05	Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2026	CI
Feb. 05	Illumina Q4 Non-GAAP Earnings, Revenue Rise; 2026 Outlook Set	MT
Feb. 05	Earnings Flash (ILMN) Illumina, Inc. Posts Q4 Adjusted EPS $1.35 per Share, vs. FactSet Est of $1.24	MT
Feb. 05	Earnings Flash (ILMN) Illumina, Inc. Reports Q4 Revenue $1.16B, vs. FactSet Est of $1.12B	MT
Feb. 05	Illumina, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 28, 2025	CI
Feb. 03	Illumina, Inc. and the San Diego Zoo Wildlife Alliance Partner to Sequence the Frozen Zoo	CI
Jan. 30	Illumina, Inc. completed the acquisition of SomaLogic, Inc., Sengenics Corporation LLC and Sengenics Corporation Pte Ltd from Standard BioTools Inc..	CI
Jan. 30	Standard BioTools Completes $350 Million Sale of SomaLogic to Illuminia	MT
Jan. 28	The Dollar's Drop Is a Warning Shot
Jan. 28	Devyser Enters Strategic Agreement with Illumina	FW
Jan. 28	Devyser Enters Strategic Supply Agreement with Illumina to Offer Sequencing Instruments and Products	CI
Jan. 27	Spenda Limited Announces Resignation of Francis Desouza as an Executive and Director, Effective January 27, 2026	CI
Jan. 20	Illumina Secures Reimbursement of Nearly $3,000 Per TruSight Test	MT
Jan. 20	Illumina, Inc. Secures CMS Reimbursement for TruSight Oncology Comprehensive, Expanding Access to Precision Oncology	CI
Jan. 20	Illumina secures CMS reimbursement for TruSight Oncology Comprehensive, expanding access to precision oncology	RE
Jan. 15	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
Jan. 13	Illumina CEO Sees Big Growth Opportunity in China	MT
Jan. 13	Illumina Announces Alliance Framework with AstraZeneca, Merck, and Eli Lilly and Company	CI
Jan. 13	Illumina, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 07:30 AM
Jan. 13	Illumina introduces Billion Cell Atlas, genome-wide genetic perturbation dataset	RE
Jan. 13	Illumina introduces billion cell atlas to accelerate AI and drug discovery	RE
Jan. 13	Illumina unveils dataset to speed up AI-powered drug discovery	RE
Jan. 13	Illumina Introduces Genetic Perturbation Dataset to Further AI Drug Discovery	MT

Illumina, Inc. is engaged in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Its products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its product categories include Instruments, Kits & Reagents, Selection Tools, and Software & Analysis. Its Instruments category include sequencing platforms, microarray scanners, and IVD instruments. Its Kits & Reagents category consists of library preparation kits, sequencing reagents, microarray kits, clinical research products, and IVD products. Its Selection Tools category include Library Prep & Array Kit Selector, Gene Panel & Array Finder, DesignStudio Custom Assay Designer, and other. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training. It is also a developer of an emerging and highly differentiated single-cell technology.

Employees

9,000

Sector

Advanced Medical Equipment & Technology

Calendar

Apr. 27 - Q1 2026 Earnings Release (Projected)

More about the company